This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
JERUSALEM, (GLOBE NEWSWIRE) — Brainsway Ltd. (TASE:BRIN), the leader in the development of advanced noninvasive treatments for brain disorders, announced today the start of Yaacov Michlin’s tenure as CEO. Mr. Michlin brings decades of experience in growing biomedical organizations. He joined Brainsway in 2015 serving as a director on its board providing exceptional guidance and knowledge of the industry.
“We are pleased to welcome Yaacov as CEO as he possesses the right blend of strategic acumen, interpersonal skills, and management capabilities necessary to maximize Brainsway’s potential,” said Dr. David Zacut, outgoing CEO and Chairman of the Board at Brainsway. Among his many goals, Yaccov aims to make Brainsway Deep Transcranial Magnetic Stimulation, or Deep TMS, a recognizable treatment currently for major depression and in the future for other brain disorders.
For the past eight years, Michlin has served as president and CEO of Yissum, the technology transfer company of Israel’s Hebrew University in Jerusalem. At Yissum, he facilitated and oversaw numerous corporate transactions and initiatives in partnership with corporations across the globe. Michlin plans to leverage this experience and being able to broker corporate partnerships to expand the footprint of Deep TMS within psychiatry and other areas of brain disorders.
“I am grateful to lead an incredible organization filled with diligent, creative, and highly skilled employees that have developed world class products and continue to innovate and develop next generations of products to address various brain disorders,” said Michlin. “My aim is to expand Brainsway leadership in providing noninvasive, safe treatments for depression – and in the future more brain disorders – by expanding its current footprint in the United States, Europe and other areas and by continuing the investment in its R&D and deep science that backs Brainsway’s current and future products.”
Mr. Michlin is a lawyer and economist by training, and holds an MBA from the Technion in high-tech company management. We greatly appreciate Dr. David Zacut for bridging the gap as interim CEO with his passion and extensive knowledge. As we head into Q2, our organization is grateful to have Mr. Michlin lead Brainsway and look forward to high growth and success in the coming years.